ISSUE 1420
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
The FDA has approved ospemifene (os pem’ i feen; Osphena – Shionogi), an estrogen agonist/antagonist, for oral treatment of moderate to severe dyspareunia in postmenopausal women. Ospemifene is the fourth estrogen agonist/antagonist to be marketed in the US, but it is the only one that has an estrogen-like effect on vaginal epithelium. The other three, tamoxifen (Nolvadex, and generics), toremifene (Fareston), and raloxifene (Evista), are used for treatment and prevention of breast cancer and osteoporosis.
TREATMENT OF DYSPAREUNIA — Vulvovaginal atrophy is common among postmenopausal women and may cause irritation, itching, vaginal dryness and pain with intercourse (dyspareunia). Over-the-counter nonhormonal moisturizers and lubricants (Replens, K-Y, and others) may provide adequate symptom relief for some women, but do not treat the underlying
... more1. Drugs for female sexual dysfunction. Med Lett Drugs Ther 2010; 52:100.
3. GT Wurz et al. Ospemifene, vulvovaginal atrophy, and breast cancer. Maturitas 2013. Jan 15 (epub).
7. Wholesale acquisition cost (WAC). Source: $ource® Monthly (Selected from FDB MedKnowledge™) June 5, 2013. Reprinted with permission by FDB, Inc. All rights reserved. ©2013. www.fdbhealth.com/policies/drug-pricing policy. Actual retail prices may be higher.
Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1420c
Electronic, downloadable article - $45